Description: SoftOx Solutions AS, together with its subsidiaries, operates as a medtech and clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. Its products include SafeDes+, a hand disinfectant for irritated, compromised, and eczematous skin; and EffectDesH, a surface disinfectant, which has a killing/inactivation effect on bacteria, viruses, yeast, fungi, mycobacterium, and spores. The company also provides human wound and infection treatment products comprising SoftOx Wound Irrigation solutions for acute and chronic wounds to prevent and treat infections, including biofilms; and SoftOx Anti-infectives to treat and remove topical infections in wounded and mucosal tissues, such as biofilms, AMR microbes, viruses, and fungi. In addition, it is developing antiseptic solutions for pets and livestock; and inhalation solution, a novel and self-administered inhaled drug that is in Phase II clinical trial for early treatment and prevention of influenza-like illnesses. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norway.
Home Page: soft-ox.com
Martin Linges vei 25
Fornebu,
1364
Norway
Phone:
47 94 85 95 99
Officers
| Name | Title |
|---|---|
| Mr. Thomas Bjarnsholt | CEO, Chief Medical Officer & Chief Scientific Officer |
| Ms. Ingrid Juven | COO & CFO |
| Ms. Elin Lisby Kastberg Jørgensen | International Senior Project Manager |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2655 |
| Price-to-Sales TTM: | 1.1755 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |